Clinical trial · Interventional
Know and Own Your Movement-related Metrics Via Wearable Devices
Personalized Feedback of Wearable Biological Sensor Data to Promote Active Living in Cancer Survivors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to promote daily physical activity in cancer survivors who are at high risk for type 2 diabetes (T2D) by using a personalized biological-based feedback strategy. T2D is one of the most common co-occurring conditions in cancer survivors and can worsen cancer-related health outcomes, especially in those who are insufficiently active. The investigators hypothesize that seeing the immediate impacts of exercise on their biological status will motivate cancer survivors to exercise. The investigators will use real-time data from continuous glucose monitor to demonstrate the acute impact of physical activity and measure daily activity levels using wearable trackers. As wearable sensor technology is constantly advancing, this study is the first step to exploring how researchers can use wearable sensors to help people make a direct connection between their daily behaviors and health outcomes.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Survivorship | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Glucose-based biofeedback | Behavioral | — | UNRESOLVED |
| Standard feedback | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Biofeedback Group
- interventionNames
- Behavioral: Glucose-based biofeedback
- type
- ACTIVE_COMPARATOR
- label
- Standard Care Group
- interventionNames
- Behavioral: Standard feedback
Primary outcomes (1)
- measure
- Feasibility of delivering personalized glucose-based feedback
- timeFrame
- Through study completion, an average of 3 months.
- description
- The intervention will be considered feasible if ≥ 80% of participants in the intervention group are adherent to the self-monitoring protocol and ≥ 80% of participants complete the post-intervention assessment.
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * be 18 years or older * have had a diagnosis of cancer * have completed curative-intended treatment for at least 3 months (except hormone therapy or long-term maintenance chemotherapy) * be at high-risk for type 2 diabetes based on the American Diabetes Association Type 2 Diabetes Risk Test * currently insufficiently active * capable of participating in moderate-vigorous intensity unsupervised exercise * have no current diagnosis or history of type 1 or 2 diabetes * able to speak, read, and write in English * have a smartphone with daily internet access Exclusion Criteria: * currently taking oral antidiabetic agents (OADs) * current treatment with any insulin regimen other than basal insulin, e.g. prandial or pre-mixed insulin * currently pregnant * on dialysis * have self-reported health issues that limit physical activity * work overnight shifts * unwilling to use the study devices * current participation in other exercise or weight loss-related program or intervention * currently on a low-carb diet * current use of other implanted medical devices such as pacemakers * do not have a smartphone that is compatible with the Fitbit and the LibreLink apps
References
Publications (1)
- DERIVEDLiao Y, Schembre SM, Brannon GE, Pan Z, Wang J, Ali S, Beg MS, Basen-Engquist KM. Using wearable biological sensors to provide personalized feedback to motivate behavioral changes: Study protocol for a randomized controlled physical activity intervention in cancer survivors (Project KNOWN). PLoS One. 2022 Sep 13;17(9):e0274492. doi: 10.1371/journal.pone.0274492. eCollection 2022. PMID 36099282